Antibody Response to SARS-CoV-2 Vaccination in Patients with End-Stage Kidney Disease on Hemodialysis
Patients with end-stage kidney disease on hemodialysis (ESKD-HD) have a high risk of contracting severe COVID-19. Vaccination can help reduce disease severity, but the immune dysregulation observed in these patients may result in an inadequate antibody response. Therefore, we aimed to evaluate the i...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/11/12/1802 |
| _version_ | 1797379145723805696 |
|---|---|
| author | Rizky Andhika Muhammad Iqbal Anand Marita Restie Tiara Josephine Debora Hofiya Djauhari Evan Susandi Adnes Mareta Asep Riswoko Nopi Susilawati Agnes Rengga Indrati Bachti Alisjahbana Rudi Supriyadi |
| author_facet | Rizky Andhika Muhammad Iqbal Anand Marita Restie Tiara Josephine Debora Hofiya Djauhari Evan Susandi Adnes Mareta Asep Riswoko Nopi Susilawati Agnes Rengga Indrati Bachti Alisjahbana Rudi Supriyadi |
| author_sort | Rizky Andhika |
| collection | DOAJ |
| description | Patients with end-stage kidney disease on hemodialysis (ESKD-HD) have a high risk of contracting severe COVID-19. Vaccination can help reduce disease severity, but the immune dysregulation observed in these patients may result in an inadequate antibody response. Therefore, we aimed to evaluate the immune response postvaccination in ESKD-HD patients. This prospective cohort study was conducted in two hemodialysis centers in Indonesia. We enrolled ESKD-HD patients (<i>n</i> = 143) pre- and postvaccination and compared them to healthy subjects (<i>n</i> = 67). SARS-CoV-2 antibody response was assessed using anti-S-RBD antibodies and SVNT % inhibition tests. We performed bivariate and multivariate analysis to determine factors associated with SARS-CoV-2 antibody levels. Seropositive conversion was observed in 97% ESKD-HD subjects postvaccination. Compared with healthy subjects, ESKD-HD patients showed a comparable anti-S-RBD antibody titer postvaccination. mRNA vaccines remained a significant factor for the high immune response, while hypoalbuminemia correlated with lower immune response. In conclusion, ESKD-HD patients showed a robust immune response postvaccination. mRNA vaccines induced a stronger antibody response than other vaccines. Lower levels of serum albumin correlate with lower immune responses in ESKD-HD patients after vaccination. |
| first_indexed | 2024-03-08T20:18:00Z |
| format | Article |
| id | doaj.art-474194d7aae0446fb1c838677f15e103 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-08T20:18:00Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-474194d7aae0446fb1c838677f15e1032023-12-22T14:47:12ZengMDPI AGVaccines2076-393X2023-12-011112180210.3390/vaccines11121802Antibody Response to SARS-CoV-2 Vaccination in Patients with End-Stage Kidney Disease on HemodialysisRizky Andhika0Muhammad Iqbal Anand1Marita Restie Tiara2Josephine Debora3Hofiya Djauhari4Evan Susandi5Adnes Mareta6Asep Riswoko7Nopi Susilawati8Agnes Rengga Indrati9Bachti Alisjahbana10Rudi Supriyadi11Division of Nephrology and Hypertension, Internal Medicine Department, Hasan Sadikin General Hospital, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, IndonesiaInternal Medicine Department, Hasan Sadikin General Hospital, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, IndonesiaResearch Center for Care and Control of Infectious Diseases (RC3ID), Universitas Padjajaran, Bandung 40161, IndonesiaInternal Medicine Department, Hasan Sadikin General Hospital, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, IndonesiaResearch Center for Care and Control of Infectious Diseases (RC3ID), Universitas Padjajaran, Bandung 40161, IndonesiaInternal Medicine Department, Hasan Sadikin General Hospital, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, IndonesiaResearch Center for Care and Control of Infectious Diseases (RC3ID), Universitas Padjajaran, Bandung 40161, IndonesiaResearch Center for Polymer Technology—National Research and Innovation Agency (BRIN), Jakarta 10340, IndonesiaResearch Center for Care and Control of Infectious Diseases (RC3ID), Universitas Padjajaran, Bandung 40161, IndonesiaDepartment of Clinical Pathology, Hasan Sadikin General Hospital, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, IndonesiaResearch Center for Care and Control of Infectious Diseases (RC3ID), Universitas Padjajaran, Bandung 40161, IndonesiaDivision of Nephrology and Hypertension, Internal Medicine Department, Hasan Sadikin General Hospital, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, IndonesiaPatients with end-stage kidney disease on hemodialysis (ESKD-HD) have a high risk of contracting severe COVID-19. Vaccination can help reduce disease severity, but the immune dysregulation observed in these patients may result in an inadequate antibody response. Therefore, we aimed to evaluate the immune response postvaccination in ESKD-HD patients. This prospective cohort study was conducted in two hemodialysis centers in Indonesia. We enrolled ESKD-HD patients (<i>n</i> = 143) pre- and postvaccination and compared them to healthy subjects (<i>n</i> = 67). SARS-CoV-2 antibody response was assessed using anti-S-RBD antibodies and SVNT % inhibition tests. We performed bivariate and multivariate analysis to determine factors associated with SARS-CoV-2 antibody levels. Seropositive conversion was observed in 97% ESKD-HD subjects postvaccination. Compared with healthy subjects, ESKD-HD patients showed a comparable anti-S-RBD antibody titer postvaccination. mRNA vaccines remained a significant factor for the high immune response, while hypoalbuminemia correlated with lower immune response. In conclusion, ESKD-HD patients showed a robust immune response postvaccination. mRNA vaccines induced a stronger antibody response than other vaccines. Lower levels of serum albumin correlate with lower immune responses in ESKD-HD patients after vaccination.https://www.mdpi.com/2076-393X/11/12/1802COVID-19chronic kidney diseaseantibody levelvaccination |
| spellingShingle | Rizky Andhika Muhammad Iqbal Anand Marita Restie Tiara Josephine Debora Hofiya Djauhari Evan Susandi Adnes Mareta Asep Riswoko Nopi Susilawati Agnes Rengga Indrati Bachti Alisjahbana Rudi Supriyadi Antibody Response to SARS-CoV-2 Vaccination in Patients with End-Stage Kidney Disease on Hemodialysis Vaccines COVID-19 chronic kidney disease antibody level vaccination |
| title | Antibody Response to SARS-CoV-2 Vaccination in Patients with End-Stage Kidney Disease on Hemodialysis |
| title_full | Antibody Response to SARS-CoV-2 Vaccination in Patients with End-Stage Kidney Disease on Hemodialysis |
| title_fullStr | Antibody Response to SARS-CoV-2 Vaccination in Patients with End-Stage Kidney Disease on Hemodialysis |
| title_full_unstemmed | Antibody Response to SARS-CoV-2 Vaccination in Patients with End-Stage Kidney Disease on Hemodialysis |
| title_short | Antibody Response to SARS-CoV-2 Vaccination in Patients with End-Stage Kidney Disease on Hemodialysis |
| title_sort | antibody response to sars cov 2 vaccination in patients with end stage kidney disease on hemodialysis |
| topic | COVID-19 chronic kidney disease antibody level vaccination |
| url | https://www.mdpi.com/2076-393X/11/12/1802 |
| work_keys_str_mv | AT rizkyandhika antibodyresponsetosarscov2vaccinationinpatientswithendstagekidneydiseaseonhemodialysis AT muhammadiqbalanand antibodyresponsetosarscov2vaccinationinpatientswithendstagekidneydiseaseonhemodialysis AT maritarestietiara antibodyresponsetosarscov2vaccinationinpatientswithendstagekidneydiseaseonhemodialysis AT josephinedebora antibodyresponsetosarscov2vaccinationinpatientswithendstagekidneydiseaseonhemodialysis AT hofiyadjauhari antibodyresponsetosarscov2vaccinationinpatientswithendstagekidneydiseaseonhemodialysis AT evansusandi antibodyresponsetosarscov2vaccinationinpatientswithendstagekidneydiseaseonhemodialysis AT adnesmareta antibodyresponsetosarscov2vaccinationinpatientswithendstagekidneydiseaseonhemodialysis AT asepriswoko antibodyresponsetosarscov2vaccinationinpatientswithendstagekidneydiseaseonhemodialysis AT nopisusilawati antibodyresponsetosarscov2vaccinationinpatientswithendstagekidneydiseaseonhemodialysis AT agnesrenggaindrati antibodyresponsetosarscov2vaccinationinpatientswithendstagekidneydiseaseonhemodialysis AT bachtialisjahbana antibodyresponsetosarscov2vaccinationinpatientswithendstagekidneydiseaseonhemodialysis AT rudisupriyadi antibodyresponsetosarscov2vaccinationinpatientswithendstagekidneydiseaseonhemodialysis |